
CLAIMS









What is claimed is:

1. A compound wherein the compound has the structure of Formula I




Formula I ,

or a pharmaceutically acceptable salt thereof,

wherein R^A is $-CO_2H$, $-CO_2R^B$, -CN, tetrazolyl, $-C(=O)NH_2$, $-C(=O)NHR^B$, $-C(=O)NHSO_2R^B$ or $-C(=O)NHCH_2CH_2SO_3H$ or a carboxylic acid isostere selected from the group consisting of , , , , , , , , and ;

wherein R^B is -H or $-C_1$-C_4 alkyl, or has the structure of one of:


;

L^1 is absent or substituted or unsubstituted C_1-C_6 alkylene, substituted or unsubstituted C_3-C_6 cycloalkylene, C_1-C_6 fluoroalkylene, substituted or unsubstituted C_1-C_6 heteroalkylene;

L^2 is absent;

Ring B is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where if Ring B is substituted then Ring B is substituted with 1, 2, or 3 independently selected R^H;

Ring A is a 5 membered heteroarene selected from one of:



,

wherein the dashed line indicates the point of attachment of Ring A to Ring B;

wherein R^C is -CN, -F, -Cl, -Br, -I, -OC_1-C_4 alkyl, or C_1-C_4 fluoroalkyl,

and R^D is -N(R^F)-C(=O)XCH(R^G)-CY, -N(R^F)C(=O)XC(R^G)$_2$-CY, -N(R^F)C(=O)X-CY, -C(=O)N(R^F)CH(R^G)X-CY, or -C(=O)-N(R^F)C(R^G)$_2$X-CY, wherein X is absent, -O-, -NH- or -CH_2-;

R^E is -H, -C_1-C_4 alkyl or -C_1-C_4 fluoroalkyl;

R^F is -H or C_1-C_4 alkyl;

R^G is independently selected from R^E, or one R^G is C_1-C_4 alkyl and is taken together with the carbon atom to which R^G is attached and the carbon or heteroatom to which CY is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other R^G, if present, is as defined for R^E;

CY is substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_3-C_{10} cycloalkyl, substituted or unsubstituted C_2-C_{10} heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected R^H;

wherein each R^H is independently selected from -H, halogen, -CN, -NO_2, -OH,

$-OR^J$, $-SR^J$, $-S(=O)R^J$, $-S(=O)_2R^J$, $-N(R^J)S(=O)_2R^J$, $-S(=O)_2N(R^L)_2$, $-C(=O)R^J$, $OC(=O)R^J$, $-C(=O)OR^J$, $-OC(=O)OR^J$, $-N(R^L)_2$, $-C(=O)N(R^L)_2$, $-OC(=O)N(R^L)_2$, $-N(R^J)C(=O)N(R^L)_2$, $-N(R^J)C(=O)R^J$, $-N(R^J)C(=O)OR^J$, C_1-C_4 alkyl, C_1-C_4 fluoroalkyl, C_1-C_4 fluoroalkoxy, C_1-C_4 alkoxy, and C_1-C_4 heteroalkyl,

wherein each R^J is independently substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_1-C_6 heteroalkyl, C_1-C_6 fluoroalkyl, substituted or unsubstituted C_3-C_6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C_1-C_4 alkylene-(substituted or unsubstituted C_3-C_6 cycloalkyl), -C_1-C_4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C_1-C_4 alkylene-(substituted or unsubstituted aryl), or -C_1-C_4 alkylene-(substituted or unsubstituted heteroaryl);


wherein each R^L is independently -H, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_1-C_6 heteroalkyl, C_1-C_6 fluoroalkyl, substituted or unsubstituted C_3-C_6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C_1-C_4 alkylene-(substituted or unsubstituted cycloalkyl), -C_1-C_4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C_1-C_4 alkylene(substituted or unsubstituted aryl), or -C_1-C_4 alkylene-(substituted or unsubstituted heteroaryl),

or when R^H is $-S(=O)_2N(R^L)_2$, $-N(R^L)_2$, $-C(=O)N(R^L)_2$, $-OC(=O)N(R^L)_2$ or $N(R^F)C(=O)N(R^L)_2$, each R^L is independently -H or C_1-C_6 alkyl, or the R^L groups independently are C_1-C_6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle;

Ring C is substituted or unsubstituted C_3-C_{10} cycloalkylene, substituted or unsubstituted C_2-C_{10} heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where if ring C is substituted then ring C is substituted with 1, 2, or 3 independently selected R^H, wherein R^H is as previously defined, wherein if R^J, R^L and or R^H is substituted, it is substituted with one or more selected from alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, halo, nitro, haloalkyl, fluoroalkyl, fluoroalkoxy, and amino, including mono- and di-substituted amino groups, halide, - CN, -NO_2, or LsRs, wherein each Ls is independently selected from a bond, -O-, - C(=O)-, -C(=O) O -, -S-, -S(=O)-, -$S(=O)_2$-, -NH-, -NHC(=O)-, -C(=O)NH-, $S(=O)_2$NH-, - $NHS(=O)_2$, -OC(=O)NH-, -NHC(=O)O-, or -(C_1-C_6 alkylene)-; and each Rs is selected from -H, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl.

2. The compound of claim 1 wherein R^D is -N(R^F)-C(=O)XCH(R^G)-CY, -N(R^F)C(=O)XC(R^G)$_2$-CY, -N(R^F)C(=O)X-CY, wherein R^F and each R^G independently are -H or C_1-C_4 alkyl.

3. The compound of claim 2 wherein Ring A has the structure:



;

wherein Ring B is substituted or unsubstituted arylene and Ring C is substituted or unsubstituted arylene or is substituted or unsubstituted C_3-C_{10} cycloalkylene.

4. The compound of claim 2 wherein L^1 is absent or a substituted or unsubstituted substituted C_1-C_4 alkylene or a substituted or unsubstituted C_3 cycloalkylene.


5. The compound of claim 2 wherein L^1 is -CH_2-,  or -$C(CH_3)_2$-.

6. The compound of claim 2 wherein R^C is -CN, –F, -Cl or -CF_3 and R^D is -$N(R^F)C(=O)XCH(R^G)$-CY.

7. The compound of claim 2 wherein X is -NH- or -O; wherein R^G and each R^F, independently selected, are -H or –C_1-alkyl; wherein -CY is aryl substituted with 1 or 2 R^H independently selected from -H, -F, -Cl or –C_1-alkyl.


8. The compound of claim 2, wherein Ring C is substituted or unsubstituted arylene, where if Ring C is substituted then Ring C is substituted with 1 R^H selected from -F, -Cl or –C_1-alkyl.

9. The compound of claim 5, wherein the compound has the structure



Formula XII

wherein A^1 is =CH- or =N-; wherein Ring A is a 5-membered heteroarene having the structure of:



,

wherein R^D in claim 1 above is $-N(R^F)-C(=O)OCH(R^G)-CY$ and wherein

CY is phenyl substituted with one R^H;

R^A is $-CO_2H$ or $-CO_2R^B$;

wherein L^1 is $–CH_2-$ or  ;

R^G is -H or $-CH_3$; and

R^H independently are -H, halogen, $-CH_3$ or $-CF_3$.

10. The compound of claim 2 wherein the compound is selected from: 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]acetic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-3-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-

ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(2-Chloro-4'-{5-[1-(2-chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-methyl-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)- 1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, (R)-1-{2-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, 2-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenyl]acetic acid, 1-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenyl]cyclopropanecarboxylic acid, 1-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]cyclopropanecarboxylic acid, 2-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenyl]-2-methyl-propanoic acid, 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]-2-methyl-propanoic acid, 1-{4'-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-4-biphenylyl)cyclopropanecarboxylic acid, 1-{3-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-3-fluoro-4-biphenylyl)cyclopropanecarboxylic acid, 1-{2-Fluoro-4'-[4-fluoro-5-(1-

phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-2-fluoro-4-biphenylyl)cyclopropanecarboxylic acid, 1-(2-Chloro-4'-{5-[1-(o-chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-4-biphenylyl)cyclopropanecarboxylic acid, 1-(4-{p-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]phenyl}tolyl)cyclopropanecarboxylic acid, 1-[4-(p-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}phenyl)tolyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[p-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-2-pyridyl)phenyl]cyclopropanecarboxylic acid, 1-(2-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-2-pyridyl)-2-fluorophenyl]cyclopropanecarboxylic acid, 1-(3-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-2-pyridyl)-3-fluorophenyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[p-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl}-2-pyridyl)phenyl]cyclopropanecarboxylic acid, 1-(4-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}-2-fluorophenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl}-2-pyridyl)-2-

fluorophenyl]cyclopropanecarboxylic acid, 1-(4-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}-3-fluorophenyl)cyclopropanecarboxylic acid, and 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl}-2-pyridyl)-3-fluorophenyl]cyclopropanecarboxylic acid.

11. The compound of claim 10 wherein the compound is 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]acetic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-3-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(2-Chloro-4'-{5-[1-(2-chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-methyl-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)- 1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, or (R)-1-{2-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid.

12. The compound of claim 10 wherein the compound is (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

13. The compound of claim 1 for use in medicine.

14. A medicament for use in the treatment of a subject with a lysophosphatidic acid-dependent disease or condition, comprising the compound of claim 1, wherein the lysophosphatidic acid-dependent disease or condition is selected from fibrosis of organs including liver, kidney, lung, and heart; liver diseases including acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, and hepatic blood flow disorder; cell proliferative disease such as cancers including but not limited to solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), invasive metastasis of cancer cell; inflammatory diseases including but not limited to psoriasis, nephropathy, pneumonia; gastrointestinal tract disease including but not limited to irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion; renal disease, urinary tract-associated disease including but not limited to benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease, spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease including but not limited to obstruction of lower urinary tract, inflammatory disease of lower urinary tract including but not limited to dysuria, frequent urination;

pancreas disease, abnormal angiogenesis-associated disease including but not limited to arterial obstruction; scleroderma, brain-associated disease including but not limited to cerebral infarction, cerebral hemorrhage; nervous system diseases including but not limited to neuropathic pain, peripheral neuropathy, pruritus; and ocular disease including but not limited to age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreo-retinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring.

15. The compound of claim 10 wherein the compound is 1-{4'-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphenylyl}cyclopropanecarboxylic acid.

16. The compound of claim 1 for use in a method for treatment of a lysophosphatidic acid-dependent disease or condition in a subject in need thereof, characterized in that a therapeutically effective amount of the compound of claim 1 is administered to the subject, wherein the lysophosphatidic acid-dependent disease or condition is selected from fibrosis of organs including liver, kidney, lung, and heart; liver diseases including acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, and hepatic blood flow disorder; cell proliferative disease such as cancers including but not limited to solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), invasive metastasis of cancer cell; inflammatory diseases including but not limited to psoriasis, nephropathy, pneumonia; gastrointestinal tract disease including but

not limited to irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion; renal disease, urinary tract-associated disease including but not limited to benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease, spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease including but not limited to obstruction of lower urinary tract, inflammatory disease of lower urinary tract including but not limited to dysuria, frequent urination; pancreas disease, abnormal angiogenesis-associated disease including but not limited to arterial obstruction; scleroderma, brain-associated disease including but not limited to cerebral infarction, cerebral hemorrhage; nervous system diseases including but not limited to neuropathic pain, peripheral neuropathy, pruritus; and ocular disease including but not limited to age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreo-retinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring..

17. The compound for use of claim 16 wherein the compound is selected from: 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]acetic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-3-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(2-Chloro-4'-{5-[1-(2-chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-methyl-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-

ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)- 1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, (R)-1-{2-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, 2-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenyl]acetic acid, 1-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenyl]cyclopropanecarboxylic acid, 1-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]cyclopropanecarboxylic acid, 2-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenyl]-2-methyl-propanoic acid, 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]-2-methyl-propanoic acid, 1-{4'-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-4-biphenylyl)cyclopropanecarboxylic acid, 1-{3-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-3-fluoro-4-biphenylyl)cyclopropanecarboxylic acid, 1-{2-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphenylyl}cyclopropanecarboxylic acid, 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-2-fluoro-4-biphenylyl)cyclopropanecarboxylic acid, 1-(2-Chloro-4'-{5-[1-(o-chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-4-biphenylyl)cyclopropanecarboxylic acid, 1-(4-{p-[4-Fluoro-5-(1-

phenylethoxycarbonylamino)-1H-pyrazol-1-yl]phenyl}tolyl)cyclopropanecarboxylic acid, 1-[4-(p-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}phenyl)tolyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[p-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-2-pyridyl)phenyl]cyclopropanecarboxylic acid, 1-(2-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-2-pyridyl)-2-fluorophenyl]cyclopropanecarboxylic acid, 1-(3-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}-2-pyridyl)-3-fluorophenyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[p-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl}-2-pyridyl)phenyl]cyclopropanecarboxylic acid, 1-(4-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}-2-fluorophenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl}-2-pyridyl)-2-fluorophenyl]cyclopropanecarboxylic acid, 1-(4-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-2-pyridyl}-3-fluorophenyl)cyclopropanecarboxylic acid, and 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl}-2-pyridyl)-3-fluorophenyl]cyclopropanecarboxylic acid.

18. The compound for use of claim 16 wherein the compound is (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

19. The compound for use of claim 16 wherein the compound is 1-{4'-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]-4-biphenylyl}cyclopropanecarboxylic acid.

20. A compound of any one of claims 10-12, 15 for use in treating a lysophosphatidic acid-dependent disease or condition or a compound for use according to claim 16, wherein the lysophosphatidic acid-dependent disease or condition is selected from fibrosis of organs including liver, kidney, lung, and heart; liver diseases including acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, and hepatic blood flow disorder; cell proliferative disease such as cancers including but not limited to solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), invasive metastasis of cancer cell; inflammatory diseases including but not limited to psoriasis, nephropathy, pneumonia; gastrointestinal tract disease including but not limited to irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion; renal disease, urinary tract-associated disease including but not limited to benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease, spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease including but not limited to obstruction of lower urinary tract, inflammatory disease of lower urinary tract including but not limited to dysuria, frequent urination; pancreas disease, abnormal angiogenesis-associated disease including but not limited to arterial obstruction; scleroderma, brain-

associated disease including but not limited to cerebral infarction, cerebral hemorrhage; nervous system diseases including but not limited to neuropathic pain, peripheral neuropathy, pruritus; and ocular disease including but not limited to age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreo-retinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring.

21. The compound for use according to claim 20 wherein the lysophosphatidic acid-dependent disease or condition is fibrosis of the organs.

22. The compound for use according to claim 20 wherein the lysophosphatidic acid-dependent disease or condition is a liver disease.

23. The compound for use according to claim 20 wherein the lysophosphatidic acid-dependent disease or condition is a renal disease.

24. The compound for use according to claim 20 wherein the lysophosphatidic acid-dependent disease or condition is diabetic nephropathy.

25. A pharmaceutically acceptable formulation comprising a compound of any one of claims 10-12, 15 and one or more pharmaceutically acceptable excipients.